This provider's $24.5M in total Medicare payments ranks in the 96th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 1270% from 2014 to 2019.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 7274% in 2018
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $55.00 | $22.99 | 2.39x | $32.01 | $1.4M | 63.1K | 19.6K |
| 2015 | $73.57 | $22.91 | 3.21x | $50.66 | $692.0K | 29.7K | 14.4K |
| 2016 | $483.63 | $57.91 | 8.35x | $425.72 | $170.4K | 3.1K | 2.4K |
| 2017 | $104.06 | $14.04 | 7.41x | $90.02 | $33.2K | 2.3K | 2.3K |
| 2018 | $438.28 | $149.48 | 2.93x | $288.80 | $2.4M | 3.8K | 3.8K |
| 2019 | $1.4K | $714.05 | 1.96x | $684.01 | $19.7M | 24.7K | 24.6K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 81408 | Molecular pathology procedure level 9 | 4.6K | $8.9M | $2.0K | 1.43x |
| 81201 | Gene analysis (adenomatous polyposis coli), full gene sequence | 4.4K | $3.4M | $762.37 | 1.99x |
| 81317 | Gene analysis (postmeiotic segregation increased 2 [S cerevisiae]) full sequence analysis | 4.4K | $2.9M | $665.94 | 2.06x |
| 81298 | Gene analysis (mutS homolog 6 [E coli]) full sequence analysis | 4.5K | $2.8M | $628.45 | 1.98x |
| 81295 | Gene analysis (mutS homolog 2, colon cancer, nonpolyposis type 1) full sequence analysis | 4.5K | $1.7M | $373.74 | 2.07x |
| 81406 | Molecular pathology procedure level 7 | 4.6K | $1.3M | $276.53 | 2.56x |
| 81162 | Gene analysis (breast cancer 1 and 2) full sequence and duplication or deletion variants | 557 | $1.1M | $2.0K | 2.14x |
| G0431 | Drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter | 5.3K | $516.6K | $97.10 | 2.06x |
| 82649 | Dihydromorphinone (drug) level | 3.3K | $114.7K | $34.30 | 1.94x |
| 83789 | Mass spectrometry (laboratory testing method) | 4.2K | $101.9K | $24.09 | 3.30x |
| 82646 | Dihydrocodeinone (drug) measurement | 3.3K | $92.1K | $27.55 | 1.94x |
| 83925 | Opiates (drug) measurement | 3.4K | $87.0K | $25.97 | 3.37x |
| 83992 | PCP drug level | 4.3K | $83.8K | $19.61 | 2.06x |
| G0482 | Drug test def 15-21 classes | 486 | $79.1K | $162.71 | 12.53x |
| 82542 | Chemical analysis using chromatography technique | 3.2K | $75.9K | $24.09 | 1.98x |
| 80154 | Benzodiazepines level | 3.0K | $72.9K | $24.68 | 2.06x |
| 83840 | Methadone level | 3.2K | $68.7K | $21.78 | 1.98x |
| 83805 | Meprobamate (sedative) level | 2.9K | $68.0K | $23.53 | 4.61x |
| 80160 | Desipramine level | 2.9K | $66.0K | $22.96 | 2.06x |
| 82145 | Amphetamine or methamphetamine level | 3.1K | $64.3K | $20.75 | 3.96x |
This provider submits charges 1.95 times higher than what Medicare actually pays.
A markup ratio of 1.95x means for every $100 Medicare pays, this provider initially charges $195. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data